Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. (PIRS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PIRS · as of Jun 9, 2026
Key Statistics
Explore Pieris Pharmaceuticals, Inc. Data
pirs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 2 · Buy rate: 100.0%
Competitors & Peers
pirs competitorsPIRS
ATON
CSCI
ELEV
IMNN
KAStock Performance
Full HistoryAbout Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin …
what is pieris pharmaceuticals, inc. · pirs stock overview · pieris pharmaceuticals, inc. company profile · who is pieris pharmaceuticals, inc. ceo · pirs NASDAQ · pieris pharmaceuticals, inc. headquarters · pieris pharmaceuticals, inc. business segments
About Stock Overview & Key Data
Pieris Pharmaceuticals, Inc. (PIRS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 2, 2015. As of the latest trading session, PIRS stock price is $13.60, with a market capitalization of $18.0M. The stock has returned -4.96% over the past 12 months and +0.00% year-to-date.
According to 2 Wall Street analysts, the consensus rating for Pieris Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Pieris Pharmaceuticals, Inc. reported revenue of — and net income of -$41.7M. For detailed data — including Pieris Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Pieris Pharmaceuticals, Inc. (PIRS) stock price is $13.60. The stock is traded on NASDAQ under the ticker symbol PIRS. The 52-week range is $6.20 – $22.32.